BioBlast Pharma Reports Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Lower Than Expected R&D Expenses Drive 3Q EPS Beat for BioBlast Pharma (ORPN); Oppenheimer Reiterates Outperform
November 19, 2015 7:33 AM ESTOppenheimer reiterated an Outperform rating and $32.00 price target on Bio Blast Pharma (NASDAQ: ORPN) following the company's 3Q earnings report. ORPN reported a loss of $(0.25)/share vs. consensus of $(0.29), primarily due to lower than expected R&D expenses. In 3Q15, ORPN announced positive... More
BioBlast Pharma (ORPN) Tops Q3 EPS by 4c
November 17, 2015 8:03 AM ESTBioBlast Pharma (NASDAQ: ORPN) reported Q3 EPS of ($0.25), $0.04 better than the analyst estimate of ($0.29).
BioBlast ended the third quarter of 2015 with $23.1 million in cash and short-term bank deposits, total quarterly expenses were $3.6 million whereas total quarterly expenses excluding stock based compensation were $3.0 million.
On... More
